ストックスクリーナーアプリを入手
37.53
9.19%
2.59
Cue Biopharma Inc (CUE) 最新ニュース
Cue Biopharma (NASDAQ:CUE) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Cue Biopharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Cue Biopharma (CUE) Stock Surges Following Financing Deal and Le - GuruFocus
Cue Biopharma Stock Nearly Doubles After Allergy Drug Deal, New CEO and $30 Million Raise - TechStock²
Cue Biopharma jumps as investors react to Ascendant-221 licensing deal and fresh financing news - Quiver Quantitative
Cue Biopharma licenses Ascendant-221 and raises new capital - TipRanks
Cue Biopharma Raises $30 Million in Private Placement to Advance Immunology Pipeline - citybiz
MSN Money - MSN
Cue resets strategy with new CEO, pipeline deal and $30m financing - The Pharma Letter
Cue Biopharma raises $30M in private placement - MSN
Cue Biopharma appoints Shao-Lee Lin as CEO and president - Investing.com UK
CUE Stock Quote Price and Forecast - CNN
CUE Stock Price, Quote & Chart | CUE BIOPHARMA INC (NASDAQ:CUE) - ChartMill
Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving? - Benzinga
$Cue Biopharma (CUE.US)$ - Moomoo
Cue Biopharma secures $30M private placement financing - Investing.com UK
Cue Biopharma Secures $30 Million Financing and New CEO - Intellectia AI
Cue Biopharma (CUE) Secures $30M in Private Placement Financing - GuruFocus
Cue Biopharma Names Lin as CEO, Secures Exclusive License Agreement With Ascendant Health Sciences - Moomoo
Cue Biopharma unveils leadership changes, pipeline milestones and financing to drive phase 2 strategy - Traders Union
Cue Biopharma secures $30M private placement financing By Investing.com - Investing.com Australia
Cue Biopharma Announces $30 Million Private P - Moomoo
Cue Biopharma licenses anti-IgE antibody for allergic diseases By Investing.com - Investing.com South Africa
Cue Biopharma appoints Shao-Lee Lin as CEO and president By Investing.com - Investing.com Australia
Cue Biopharma lines up $30M to fund pipeline and Ascendant-221 - Stock Titan
Cue Biopharma licenses anti-IgE antibody for allergic diseases - Investing.com
Cue pays $15M for allergy drug, targets food allergy trial - Stock Titan
Cue Biopharma Announces $30 Million PIPE Financing Agreement to Advance Clinical Pipeline - Quiver Quantitative
Press Release: Cue Biopharma Announces $30 Million Private Placement - Moomoo
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody - The Manila Times
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company - The Manila Times
CUE - Finviz
Cue Biopharma, Inc. Revenue Breakdown – SWB:1UC0 - TradingView
Current ratio of Cue Biopharma, Inc. – SWB:1UC0 - TradingView
Taxes of Cue Biopharma, Inc. – SWB:1UC0 - TradingView
Cue Biopharma, Inc. Trade Ideas — SWB:1UC0 - TradingView
Cue Biopharma (Nasdaq: CUE) adds Ascendant-221 and raises $30M - Stock Titan
Cue Biopharma (CUE) price target increased by 2,900.00% to 122.40 - MSN
CUE stock on track for best day in history — why is retail optimistic? - MSN
Cue Biopharma (FRA:1UC0) Unearned Income - GuruFocus
Cue Biopharma, Inc. Income Statement – GETTEX:1UC0 - TradingView
Cue Biopharma, Inc. Cash Flow – GETTEX:1UC0 - TradingView
Cue Biopharma, Inc. Trade Ideas — GETTEX:1UC0 - TradingView
Equity in earnings of Cue Biopharma, Inc. – LSX:A426PN - TradingView
Cue Biopharma, Inc. Cash Flow – LSX:A426PN - TradingView
Equity in earnings of Cue Biopharma, Inc. – GETTEX:1UC0 - TradingView
Net debt of Cue Biopharma, Inc. – GETTEX:1UC0 - TradingView
Cue Biopharma, Inc. Trade Ideas — LSX:A426PN - TradingView
Cue Biopharma, Inc. Balance Sheet – LSX:A426PN - TradingView
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):